Biomarker Identification Drives Research and Drug Developmen

Ranee Mehra, MD, and colleagues detail treatment updates across lung cancer subtypes, including navigating the array of available ALK inhibitors in NSCLC.

Related Keywords

Maryland , United States , Baltimore , University Of Maryland , Samuel Rosner , Ranee Mehra , University Of Maryland Medical System , National Comprehensive Cancer Network , Stewart Greenebaum Comprehensive Cancer Center , Hematology Medical Oncology Fellowship Program , Science Summit , Neck Medical Oncology , Medical Oncologyat , Maryland Medical System , Hematology Medical Oncology Fellowship , Displays Mixed Results , Though Interest , Non Small Cell Lung Cancer , Small Cell Lung Cancer , Nsclc , Immunotherapy Approaches , Biomarkers , Kras G12c Mutated Nsclc , Alk Inhibitors , Katherinea Scilla , D , Naacp ,